Published in Infect Immun on June 01, 1991
Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun (2006) 2.09
Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut (1997) 1.96
Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun (1998) 1.63
Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun (1995) 1.35
Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases. Emerg Infect Dis (1999) 1.29
GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother (2001) 1.25
Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun (1999) 1.25
Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun (2001) 1.23
Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem (2011) 1.19
Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother (1996) 1.17
Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci (2010) 1.13
A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine (2009) 1.08
Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother (1997) 1.07
A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model. Clin Vaccine Immunol (2013) 1.03
Neutralization of Clostridium difficile toxin A using antibody combinations. MAbs (2011) 1.01
New advances in the treatment of Clostridium difficile infection (CDI). Ther Clin Risk Manag (2008) 0.98
The host immune response to Clostridium difficile infection. Ther Adv Infect Dis (2013) 0.96
Immune responses to Clostridium difficile infection. Trends Mol Med (2012) 0.95
Orally administered P22 phage tailspike protein reduces salmonella colonization in chickens: prospects of a novel therapy against bacterial infections. PLoS One (2010) 0.95
Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection. Infect Immun (2011) 0.89
Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives. Toxins (Basel) (2010) 0.88
Antibodies for treatment of Clostridium difficile infection. Clin Vaccine Immunol (2014) 0.87
Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice. Infect Immun (2000) 0.85
Immune-based treatment and prevention of Clostridium difficile infection. Hum Vaccin Immunother (2014) 0.84
Theodore E. Woodward Award. How bacterial enterotoxins work: insights from in vivo studies. Trans Am Clin Climatol Assoc (2002) 0.82
Veterinary nutraceutical medicine. Can Vet J (2000) 0.81
An update on antibody-based immunotherapies for Clostridium difficile infection. Clin Exp Gastroenterol (2016) 0.80
Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies. Infect Immun (2015) 0.80
Passive immunity against human pathogens using bovine antibodies. Clin Exp Immunol (1999) 0.79
Hyperimmune bovine colostrum as a novel therapy to combat Clostridium difficile infection. J Infect Dis (2014) 0.77
Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response. Vaccine (2013) 0.76
A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection. Infect Dis Ther (2016) 0.75
Treatment of Recurrent Clostridium difficile Diarrhea. Gastroenterol Hepatol (N Y) (2006) 0.75
Comments regarding the claimed effectiveness of bovine colostrum. Can Vet J (2000) 0.75
Equine hyperimmune serum protects mice against Clostridium difficile spore challenge. J Vet Sci (2013) 0.75
Clostridium difficile: its disease and toxins. Clin Microbiol Rev (1988) 7.26
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
Biological activities of toxins A and B of Clostridium difficile. Infect Immun (1982) 4.62
Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun (1990) 4.06
Production of Clostridium difficile antitoxin. Infect Immun (1980) 3.95
Nucleotide sequence of Clostridium difficile toxin B gene. Nucleic Acids Res (1990) 2.93
Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun (1982) 2.65
Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med (1988) 2.04
Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology (1989) 2.03
Suppression of Clostridium difficile by normal hamster cecal flora and prevention of antibiotic-associated cecitis. Infect Immun (1981) 1.66
Immunotherapeutic efficacy of bovine colostral immunoglobulins from a hyperimmunized cow against cryptosporidiosis in neonatal mice. Infect Immun (1990) 1.45
Active and passive immunization to protect against antibiotic associated caecitis in hamsters. Dev Biol Stand (1983) 1.45
Use of bovine milk concentrate containing antibody to rotavirus to treat rotavirus gastroenteritis in infants. J Infect Dis (1987) 1.44
Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with non-pathogenic strains. J Med Microbiol (1985) 1.38
Treatment of infantile E. coli gastroenteritis with specific bovine anti-E. coli milk immunoglobulins. Eur J Pediatr (1979) 1.23
Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii. Antimicrob Agents Chemother (1984) 1.14
Bovine milk immunoglobulins for passive immunity to infantile rotavirus gastroenteritis. J Clin Microbiol (1987) 1.10
Prevention of Clostridium difficile induced mortality in gnotobiotic mice by Saccharomyces boulardii. Can J Microbiol (1986) 1.04
Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters. Antimicrob Agents Chemother (1987) 1.00
Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii. Dig Dis Sci (1990) 0.92
Specific antibodies to cholera toxin in rabbit milk are protective against Vibrio cholerae-induced intestinal secretion. Immunology (1987) 0.86
Bovine lactogenic immunity against cholera toxin-related enterotoxins and Vibrio cholerae outer membranes. Infect Immun (1989) 0.80
Medium for use in antibiotic susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1976) 9.38
Modified broth-disk method for testing the antibiotic susceptibility of anaerobic bacteria. Antimicrob Agents Chemother (1973) 9.35
Fermentation of mucin and plant polysaccharides by strains of Bacteroides from the human colon. Appl Environ Microbiol (1977) 8.29
Clostridium difficile: its disease and toxins. Clin Microbiol Rev (1988) 7.26
Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun (1982) 6.88
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
Collaborative evaluation of a proposed reference dilution method of susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1979) 5.10
Biological activities of toxins A and B of Clostridium difficile. Infect Immun (1982) 4.62
Development of a micromethod for identification of anaerobic bacteria. Appl Microbiol (1975) 4.58
Fermentation of mucins and plant polysaccharides by anaerobic bacteria from the human colon. Appl Environ Microbiol (1977) 4.09
Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun (1990) 4.06
Production of Clostridium difficile antitoxin. Infect Immun (1980) 3.95
Micromethod for identification of anaerobic bacteria: design and operation of apparatus. Appl Microbiol (1975) 3.80
Enzyme-linked immunosorbent assay for Clostridium difficile toxin A. J Clin Microbiol (1983) 3.40
Nucleotide sequence of Clostridium difficile toxin B gene. Nucleic Acids Res (1990) 2.93
Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Infect Immun (1986) 2.89
Investigation of an outbreak of antibiotic-associated colitis by various typing methods. J Clin Microbiol (1982) 2.86
Arginine, a growth-limiting factor for Eubacterium lentum. J Bacteriol (1976) 2.67
Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun (1982) 2.65
Production by Salmonella typhimurium of 2,3-dihydroxybenzoylserine, and its stimulation of growth in human serum. J Infect Dis (1970) 2.62
Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.49
Medium-dependent inhibition of Peptostreptococcus anaerobius by sodium polyanetholsulfonate in blood culture media. J Clin Microbiol (1976) 2.46
Monoclonal and specific polyclonal antibodies for immunoassay of Clostridium difficile toxin A. J Clin Microbiol (1985) 2.46
Production of antitoxins to two toxins of Clostridium difficile and immunological comparison of the toxins by cross-neutralization studies. Infect Immun (1982) 2.14
The enterotoxin of Bacteroides fragilis is a metalloprotease. Infect Immun (1995) 2.06
Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun (1986) 2.01
Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun (1988) 2.00
Purification and characterization of an enterotoxin from Bacteroides fragilis. Infect Immun (1992) 1.97
Commercial latex test for Clostridium difficile toxin A does not detect toxin A. J Clin Microbiol (1986) 1.92
Differential effects of Clostridium difficile toxins on tissue-cultured cells. J Clin Microbiol (1982) 1.87
Resistance of some species of Clostridium to clindamycin. Antimicrob Agents Chemother (1973) 1.81
Effect of clavulanic Acid on anaerobic bacteria resistant to Beta-lactam antibiotics. Antimicrob Agents Chemother (1978) 1.78
In vivo protection of Fusobacterium necrophorum from penicillin by Bacteroides fragilis. Antimicrob Agents Chemother (1975) 1.78
Problems associated with counterimmunoelectrophoresis assays for detecting Clostridium difficile toxin. J Clin Microbiol (1982) 1.75
Chemotherapy of an experimental Fusobacterium (Sphaerophorus) necrophorum infection in mice. Antimicrob Agents Chemother (1974) 1.71
Identification of the latex test-reactive protein of Clostridium difficile as glutamate dehydrogenase. J Clin Microbiol (1991) 1.67
Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun (1991) 1.66
Fibrinolytic activity of oral anaerobic bacteria. Arch Oral Biol (1978) 1.65
Toxin A of Clostridium difficile is a potent cytotoxin. J Clin Microbiol (1990) 1.65
Use of semisolid agar from initiation of pure Bacteroides fragilis infection in mice. Infect Immun (1976) 1.64
Bacteroides fragilis enterotoxin modulates epithelial permeability and bacterial internalization by HT-29 enterocytes. Gastroenterology (1996) 1.63
Inhibition of Bacteroides fragilis on blood agar plates and reversal of inhibition by added hemin. J Clin Microbiol (1976) 1.63
Beta-Lactamase activity in strains of Bacteroides melaninogenicus and Bacteroides oralis. Antimicrob Agents Chemother (1977) 1.62
Laminarinase (beta-glucanase) activity in Bacteroides from the human colon. Appl Environ Microbiol (1977) 1.61
Proteolytic activity of the Bacteroides fragilis enterotoxin causes fluid secretion and intestinal damage in vivo. Infect Immun (1995) 1.59
Purification of Clostridium difficile toxin A by affinity chromatography on immobilized thyroglobulin. Infect Immun (1987) 1.57
Purification and characterization of Clostridium perfringens iota toxin: dependence on two nonlinked proteins for biological activity. Infect Immun (1986) 1.57
Requirement of heme for growth of Bacteroides fragilis. Appl Environ Microbiol (1977) 1.53
Clostridium difficile toxin A in infants. J Infect Dis (1983) 1.53
Toxin A from Clostridium difficile binds to rabbit erythrocyte glycolipids with terminal Gal alpha 1-3Gal beta 1-4GlcNAc sequences. Arch Biochem Biophys (1987) 1.51
Vaspar broth-disk procedure for antibiotic susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1980) 1.50
Molecular basis for the pathological actions of Clostridium perfringens iota toxin. Infect Immun (1987) 1.47
Comparison of Clostridium sordellii toxins HT and LT with toxins A and B of C. difficile. J Med Microbiol (1992) 1.47
The Bacteroides fragilis toxin fragilysin disrupts the paracellular barrier of epithelial cells. Infect Immun (1997) 1.46
Cytochrome spectrum of an obligate anaerobe, Eubacterium lentum. J Bacteriol (1976) 1.45
Bacteriophages of Bacteroides. Rev Infect Dis (1980) 1.44
Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y. Infect Immun (1991) 1.44
Clostridium perfringens iota toxin: synergism between two proteins. Toxicon (1986) 1.43
Cholesterol-reducing bacterium from human feces. Appl Environ Microbiol (1977) 1.40
Purification and characterization of Clostridium sordellii hemorrhagic toxin and cross-reactivity with Clostridium difficile toxin A (enterotoxin). Infect Immun (1988) 1.40
Influence of pencillinase production by strains of Bacteroides melaninogenicus and Bacteriodes oralis on pencillin therapy of an experimental mixed anaerobic infection in mice. Arch Oral Biol (1976) 1.39
Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. Am J Trop Med Hyg (1992) 1.38
Cloning and characterization of the gene for the metalloprotease enterotoxin of Bacteroides fragilis. FEMS Microbiol Lett (1997) 1.36
Characterization of cross-reactive proteins detected by Culturette Brand Rapid Latex Test for Clostridium difficile. J Clin Microbiol (1988) 1.34
Comparison of culture, cytotoxicity assays, and enzyme-linked immunosorbent assay for toxin A and toxin B in the diagnosis of Clostridium difficile-related enteric disease. Diagn Microbiol Infect Dis (1986) 1.34
Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A. Infect Immun (1992) 1.32
Susceptibility of anaerobic bacteria to sulfamethoxazole/trimethoprim and routine susceptibility testing. Antimicrob Agents Chemother (1978) 1.26
Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A. J Clin Invest (1996) 1.26
Isolation of auxotrophs of Bacteroides fragilis. Can J Microbiol (1978) 1.21
High-level expression of a heterologous protein in the milk of transgenic swine using the cDNA encoding human protein C. Proc Natl Acad Sci U S A (1992) 1.20
Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother (1996) 1.17
Positive regulation of Clostridium difficile toxins. Infect Immun (1997) 1.17
Bacteriocin production by strains of Bacteroides isolated from human feces and the role of these strains in the bacterial ecology of the colon. Antimicrob Agents Chemother (1977) 1.16
Mutagenesis of the Clostridium difficile toxin B gene and effect on cytotoxic activity. Microb Pathog (1994) 1.14
TechLab and alexon Giardia enzyme-linked immunosorbent assay kits detect cyst wall protein 1. J Clin Microbiol (1999) 1.13
Role of Clostridium difficile toxins in disease. Gastroenterology (1987) 1.11
The fecapentaenes, potent mutagens from human feces. Chem Res Toxicol (1992) 1.11
Carbohydrate repression of catalase synthesis in Bacteroides fragilis. J Bacteriol (1977) 1.11
Effect of high-fiber and high-oil diets on the fecal flora of swine. Appl Environ Microbiol (1987) 1.10
Production by Clostridium spiroforme of an iotalike toxin that possesses mono(ADP-ribosyl)transferase activity: identification of a novel class of ADP-ribosyltransferases. Infect Immun (1989) 1.09
Degradation of polysaccharides by intestinal bacterial enzymes. Am J Clin Nutr (1978) 1.07
Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother (1997) 1.07
Transparent plastic incubator for the anaerobic glove box. Appl Environ Microbiol (1977) 1.06
Molecular characterization of the fragilysin pathogenicity islet of enterotoxigenic Bacteroides fragilis. Infect Immun (1998) 1.06
Characterization of enterotoxigenic Bacteroides fragilis by a toxin-specific enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol (1994) 1.04
Breakdown of psyllium hydrocolloid by strains of Bacterioides ovatus from the human intestinal tract. Can J Microbiol (1978) 1.04
Comparison of cefoxitin and cephalothin therapy of a mixed Bacteroides fragilis and Fusobacterius necrophorum infection in mice. Antimicrob Agents Chemother (1975) 1.03
Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency. Eur J Clin Microbiol Infect Dis (2011) 1.01
Chemotherapy of an experimental Bacteroides fragilis infection in mice. Antimicrob Agents Chemother (1977) 1.01
Two patterns of neutral steroid conversion in the feces of normal North Americans. Cancer Res (1974) 1.00
Rapid death of infant rhesus monkeys injected with Clostridium difficile toxins A and B: physiologic and pathologic basis. J Pediatr (1984) 1.00
Anaerobic specimen transport device. J Clin Microbiol (1975) 0.99
Cytotoxicity of Clostridium difficile toxin A for human colonic and pancreatic carcinoma cell lines. Cancer Res (1992) 0.98
Production of antisera against the enterotoxin of Bacteroides fragilis and their use in a cytotoxicity neutralization assay of HT-29 cells. Clin Diagn Lab Immunol (1994) 0.98
Construction and expression of the complete Clostridium difficile toxin A gene in Escherichia coli. Infect Immun (1991) 0.96
Clostridium difficile toxins A and B can alter epithelial permeability and promote bacterial paracellular migration through HT-29 enterocytes. Shock (2000) 0.93